Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy
Source abstract
Abstract
Abstract Immunogenic cell death (ICD) of tumor cells can produce plentiful tumor-associated antigens (TAAs) and release damage-associated molecules to communicate a danger situation. Damage-associated molecular patterns induce the antigen presentation ability of dendritic cells (DCs), activating the immune response cells and generating anti-tumor immune response. However, the immunosuppressive microenvironment in tumor tissues leads to a small amount of DCs in tumor tissues and suppresses their function, limiting the activation of immune response. Herein we report a tumor immunotherapy strategy by the combination of intravenous injection of doxorubicin (DOX)-loaded PLGA nanoparticles (DOX@P) coating with cell membranes (DOX@PM) and intratumoral injection of the lymphotactin (XCL-1)-loaded sodium alginate. The biomimetic nanocarriers facilitate the DOX targeted delivery to tumor, inducing a high degree of ICD. XCL-1 chemokines released from the in situ formed alginate hydrogel recruit a large amount of XCR-1+ DCs into the tumor tissue, which can capture more TAAs and mediate more cross-presentation of antigens to activate CD4+ and CD8+ T cells. As a result, in vivo antitumor experiments indicate that the double enhancement of immunogenic cell death and antigen presentation with this immunotherapy strategy improve the tumor therapy efficacy. This work provides a new strategy for enhanced tumor immunotherapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Cancer immunotherapy10.1126/science.342.6165.1432 ↗
2. Targeting immunosuppressive adenosine in cancer10.1038/nrc.2017.86 ↗
3. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival10.1016/j.ccr.2014.04.005 ↗
4. Turning foes to friends: targeting cancer-associated fibroblasts10.1038/s41573-018-0004-1 ↗
5. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression10.1158/0008-5472.CAN-11-2772 ↗
6. Sheddable prodrug vesicles combating adaptive immune resistance for improved photodynamic immunotherapy of cancer10.1021/acs.nanolett.9b04012 ↗
7. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment10.1002/adma.201803001 ↗
8. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
9. Artificially reprogrammed macrophages as tumor‐tropic immunosuppression‐resistant biologics to realize therapeutics production and immune activation
10. A biomimetic polymer magnetic nanocarrier polarizing tumor‐associated macrophages for potentiating immunotherapy10.1002/smll.202003543 ↗
11. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy10.1002/adma.201803322 ↗
12. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment10.1039/C6CS00592F ↗
13. Cancer immunotherapy comes of age10.1038/nature10673 ↗
14. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy10.1038/nrc3670 ↗
15. Adoptive cell transfer: a clinical path to effective cancer immunotherapy10.1038/nrc2355 ↗
16. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
17. The human vaccines project: a roadmap for cancer vaccine development10.1126/scitranslmed.aaf0685 ↗
18. Advanced biomaterials for cancer immunotherapy10.1038/s41401-020-0372-z ↗
19. Towards personalized, tumour-specific, therapeutic vaccines for cancer10.1038/nri.2017.131 ↗
20. Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity10.1002/adma.201703969 ↗
21. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery10.1021/nl500618u ↗
22. Cancer immunotherapy–revisited10.1038/nrd3500 ↗
23. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy10.1021/acsnano.8b07371 ↗
24. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
25. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme
26. Bacteria‐based cancer immunotherapy
27. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
28. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy10.1021/acs.nanolett.1c00209 ↗
29. Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
30. Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy10.1016/j.biomaterials.2020.119964 ↗
31. A polymer multicellular nanoengager for synergistic NIR-II photothermal immunotherapy
32. Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer10.1038/s41467-021-21047-0 ↗
33. A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD‐1/PD‐L1 axis10.1002/smll.201801120 ↗
34. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer10.1021/acsnano.7b00715 ↗
35. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade10.1126/science.aaf1490 ↗
36. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
37. Understanding the tumor immune microenvironment (TIME) for effective therapy10.1038/s41591-018-0014-x ↗
38. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy10.1038/s41467-021-23194-w ↗
39. Innate and adaptive immune cells in the tumor microenvironment10.1038/ni.2703 ↗
40. A highly active form of XCL1/lymphotactin functions as an effective adjuvant to recruit cross-presenting dendritic cells for induction of effector and memory CD8+ T cells10.3389/fimmu.2018.02775 ↗
41. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
42. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells10.1016/j.immuni.2009.08.027 ↗
43. Turning cold into hot: firing up the tumor microenvironment10.1016/j.trecan.2020.02.022 ↗
44. Cell membrane coating nanotechnology10.1002/adma.201706759 ↗
45. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy10.1021/acs.nanolett.7b05263 ↗
46. Improving cancer immunotherapy by cell membrane‐camouflaged nanoparticles10.1002/adfm.202004397 ↗
47. Molecular and nanoengineering approaches towards activatable cancer immunotherapy10.1039/C9CS00773C ↗
48. Advances in the application of injectable thermosensitive hydrogel systems for cancer therapy10.1166/jbn.2020.2988 ↗
49. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response10.1158/0008-5472.CAN-12-2027 ↗
50. XCL1 and XCR1 in the immune system10.1016/j.micinf.2011.10.003 ↗
51. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression
52. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting10.1146/annurev-immunol-020711-074950 ↗
53. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses10.1038/s41551-018-0262-6 ↗
54. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies10.1016/j.canlet.2018.08.028 ↗
55. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR110.4049/jimmunol.1401903 ↗
56. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
57. IL-6 in inflammation, immunity, and disease10.1101/cshperspect.a016295 ↗
58. A guide to cancer immunotherapy: from T cell basic science to clinical practice10.1038/s41577-020-0306-5 ↗
59. T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection10.1158/2326-6066.CIR-18-0277 ↗
60. The two faces of interferon-γ in cancer10.1158/1078-0432.CCR-11-0482 ↗
61. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity10.1172/JCI68395 ↗
62. Cytokines in cancer immunotherapy10.3390/cancers3043856 ↗